lifestyle.mmminimal.com

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

Written by

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target – NEWSnet – News… as it used to be

More Press Releases

April 25, 2026

Workforce Fatigue Emerging as Overlooked Safety Risk in Gulf Coast Industrial Operations

April 25, 2026

Harrisburg Web Design Company Encourages Small Businesses to Treat Their Website Like a Digital Employee

April 25, 2026

Expert Matchmaker in Portland Report by CX Research Institute

April 25, 2026

Julie Gilbert, CEO of Full Throttle Growth & Capital, Named Among NY Weekly Magazine’s Top 10 Visionary Entrepreneurs Shaping 2026